Adcendo ApS to Showcase ADCs ADCE-T02 and ADCE-D01 at AACR 2025
Adcendo ApS to Present Its Groundbreaking ADCs at AACR 2025
Adcendo ApS, a clinical-stage biotech firm specializing in cutting-edge antibody-drug conjugates (ADCs), has announced its intention to present significant data regarding its two innovative ADC candidates - ADCE-T02 and ADCE-D01 - at the upcoming American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025, in Chicago, Illinois.
Overview of ADCs
ADCs represent a revolutionary approach in cancer treatment, integrating a targeting antibody with a cytotoxic drug to directly deliver the therapeutic agent to cancer cells while sparing healthy tissues. This precise targeting has the potential to reduce side effects typically associated with traditional chemotherapies, making ADCs a promising solution for treating various malignancies.
ADCE-T02: Targeting Tissue Factor
One of the highlighted presentations will focus on ADCE-T02, a potential best-in-class ADC that employs a topoisomerase-1 (Topo-1) inhibitor to target Tissue Factor (TF). This protein is overexpressed in many solid tumors but is minimally present in healthy tissues, making it an ideal target for therapy. ADCE-T02 combines a next-generation antibody that targets TF with an exatecan-based payload, an innovative linker-payload technology known for its efficacy. Preclinical studies have shown a strong anti-tumor response across a variety of solid tumor models, and non-human primate studies indicated favorable tolerability. The ADC is currently undergoing a Phase 1 clinical trial for patients with advanced solid tumors in both Australia and the United States, with recruitment in Australia underway and U.S. enrollment expected soon (Clinical Trial ID: [NCT06597721]).
ADCE-D01: Focusing on uPARAP
The second ADC, ADCE-D01, marks a significant advancement as a first-in-class therapy targeting the urokinase plasminogen activator receptor-associated protein (uPARAP). This ADC is designed to combat tumors of mesenchymal origin, such as sarcomas, and shows exceptional preclinical efficacy and tolerability. The composition includes an optimized linker-payload technology paired with a unique uPARAP-targeting antibody. Preclinical models demonstrate strong anti-tumor activity in various mesenchymal tumors, and safety assessments in non-human primates suggest a highly favorable profile with no target-specific toxicity observed. A Phase 1 clinical trial for advanced soft tissue sarcomas is currently enrolling participants in the U.S. and is pending regulatory approval in the European Union (Clinical Trial ID: [NCT06797999]).
Scientific Insights from Adcendo
Adcendo's Chief Scientific Officer, Dr. Dominik Mumberg, expressed enthusiasm over the findings, stating, “We are thrilled to share promising preclinical results for ADCE-T02 and ADCE-D01, reflecting their strong anti-tumor capabilities across a wide range of tumor models and excellent tolerability. We eagerly anticipate progressing through the phase 1 trials to provide new therapeutic options to cancer patients.”
Presentation Details
Adcendo will present its findings in poster format, allowing attendees to engage with the research directly:
- - ADCE-T02 Presentation: A first-in-class topoisomerase-1 inhibitor-based antibody-drug conjugate against tissue factor demonstrates excellent preclinical efficacy and tolerability.
- - ADCE-D01 Presentation: A first-in-class antibody-drug conjugate against urokinase plasminogen activator receptor-associated protein (uPARAP) demonstrates excellent preclinical efficacy and tolerability.
Conclusion
The presentation of ADCE-T02 and ADCE-D01 at AACR 2025 marks a pivotal moment for Adcendo ApS and its commitment to advancing cancer therapies. As advancements in ADC technology continue to evolve, Adcendo stands at the forefront, aiming to address significant unmet medical needs in cancer treatment. For more details, follow Adcendo on their official channels or visit their website.
For additional information on antibody-drug conjugates and Adcendo’s innovative research, visit www.adcendo.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.